Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GOVX-B11
- Development stage
- Phase 1
- Lead developer
- GeoVax Labs
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
GOVX-B11 is a preventive and therapeutic HIV vaccine candidate developed by GeoVax Labs. The vaccine employs a prime-boost strategy consisting of two components: a recombinant DNA vaccine (pGA2/JS7 or GEO-D02) and a recombinant Modified Vaccinia Ankara (MVA) vaccine (MVA/HIV62B). Both components are engineered to express HIV-1 Clade B antigens (Env, Gag, and Pol) that assemble into non-infectious virus-like particles (VLPs) within the recipient's cells. These VLPs mimic the structure of the natural virus, thereby eliciting both humoral (antibody) and cellular (T-cell) immune responses. GOVX-B11 has been evaluated in Phase 1 and Phase 2a clinical trials for the prevention of HIV infection and in Phase 1 trials as a therapeutic vaccine for individuals already infected with HIV and suppressed on antiretroviral therapy (ART).
- Brand names
- GOVX-B11GOVX-B-11GOVX-B 11
- Other names
- pGA2/JS7 DNA and MVA/HIV62B vaccine
02
Targets
Gag (HIV-1 Gag polyprotein)Pol (HIV-1 Pol polyprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on GOVX-B11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GOVX-B11.